<DOC>
	<DOCNO>NCT00867750</DOCNO>
	<brief_summary>This study open patient primary HCC treat potentially curative treatment modality , surgical resection , liver transplantation percutaneous ablation . Patients satisfy study eligibility criterion randomise 1 : 1 ratio receive either Radioembolisation SIR-Spheres Microspheres standardise Transarterial Chemoembolisation procedure . Study Objectives This study evaluate compare quality life well safety efficacy RE TACE patient unresectable HCC . Patients follow minimum 12 month death wherever possible evaluation primary secondary objective study .</brief_summary>
	<brief_title>SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation Patients With Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Male female patient , age ≥ 18 year Unequivocal diagnosis primary HCC ( confirm biopsy/histology EASL criterion ) Tumour characteristic follow : Not 5 lesion If single , maximal diameter ≤ 10 cm If multiple , sum maximal diameter ≤ 15 cm Lesions satellite primary tumour le 1 cm maximal diameter include At least one quantifiable lesion hepatic MRI Preserved liver function , correspond ChildPugh class ≤ B7 ECOG performance status ≤ 2 Life expectancy ≥ 12 week Female patient childbearing potential must negative pregnancy test prior inclusion trial male female patient must agree use effective contraceptive method duration trial . Willing able provide write informed consent Patients expect undergo surgery ( resection transplantation ) within 24week period randomisation . Ascites , detectable physical examination clinically symptomatic ( patient ascites discovered imaging exclude ) . Serum transaminases &gt; 5 x ULN Lung shunt &gt; 20 % Extrahepatic disease Moderate severe portal hypertension , evidence follow criterion ( occur spite use common criterion prophylactic treatment therapy ) : History variceal haemorrhage past 2 year History hepatic encephalopathy Platelets &lt; 50.000 /ml WBC &lt; 3.000 / ml Previous TIPSS procedure Portal vein occlusion hepatofugal flow . Impaired liver function Total serum bilirubin &gt; 2.0 mg / dL Serum albumin &lt; 3.0 g /dl creatinine &gt; 2 mg / dL Chemotherapy experimental therapy within precede 4 week Previous TAE / TACE Previous radiation therapy liver lung Contraindications angiography ( severe peripheral vascular disease uncorrectable bleed diathesis ) Anatomical variant apparent 99mTcMAA scan preclude safe administration RE Any decompensated concomitant disease Female patient pregnant , breastfeeding , premenopausal practise efficient contraceptive method ( hormonal contraceptive , intrauterine device )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HCC</keyword>
	<keyword>RE</keyword>
	<keyword>Yttrium-90</keyword>
	<keyword>SIR-Spheres microspheres</keyword>
	<keyword>TACE</keyword>
	<keyword>Radioembolisation</keyword>
	<keyword>Transarterial Chemoembolisation</keyword>
</DOC>